The microbiome is pivotal in maintaining health and influencing disease by modulating essential inflammatory and immune responses. Hepatocellular carcinoma (HCC), ranking as the third most common cause of cancer-related fatalities globally, is influenced by the gut microbiome through bidirectional interactions between the gut and liver, as evidenced in both mouse models and human studies. Consequently, biomarkers based on gut microbiota represent promising non-invasive tools for the early detection of HCC. There is a growing body of evidence suggesting that the composition of the gut microbiota may play a role in the efficacy of immunotherapy in different types of cancer; thus, it could be used as a predictive biomarker. In this review, we will dissect the gut microbiome’s role as a potential predictive and diagnostic marker in HCC and evaluate the latest progress in leveraging the gut microbiome as a novel therapeutic avenue for HCC patients, with a special emphasis on immunotherapy.
微生物组通过调节关键的炎症和免疫反应，在维持健康和影响疾病方面起着核心作用。肝细胞癌（HCC）是全球癌症相关死亡的第三大常见原因，小鼠模型和人类研究均证实，肠道与肝脏之间的双向相互作用使得肠道微生物组能够影响HCC的发生发展。因此，基于肠道菌群的生物标志物有望成为HCC早期检测的非侵入性工具。越来越多的证据表明，肠道微生物群的组成可能影响不同类型癌症免疫疗法的疗效，因此可作为预测性生物标志物。本综述将剖析肠道微生物组作为HCC潜在预测和诊断标志物的作用，并评估利用肠道微生物组作为HCC患者新型治疗途径的最新进展，特别聚焦于免疫治疗领域。
The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma
肿瘤(癌症)患者之家